The Antituberculosis Drug Ethambutol Selectively Blocks Apical Growth in CMN Group Bacteria.
Members of the genus Mycobacterium are the most prevalent cause of infectious diseases. Mycobacteria have a complex cell envelope containing a peptidoglycan layer and an additional arabinogalactan polymer to which a mycolic acid bilayer is linked; this complex, multilayered cell wall composition (mAGP) is conserved among all CMN group bacteria. The arabinogalactan and mycolic acid synthesis pathways constitute effective drug targets for tuberculosis treatment. Ethambutol (EMB), a classical antituberculosis drug, inhibits the synthesis of the arabinose polymer. Although EMB acts bacteriostatically, its underlying molecular mechanism remains unclear. Here, we used Corynebacterium glutamicum and Mycobacterium phlei as model organisms to study the effects of EMB at the single-cell level. Our results demonstrate that EMB specifically blocks apical cell wall synthesis, but not cell division, explaining the bacteriostatic effect of EMB. Furthermore, the data suggest that members of the family Corynebacterineae have two dedicated machineries for cell elongation (elongasome) and cytokinesis (divisome).



Antibiotic treatment of bacterial pathogens has contributed enormously to the increase in human health. Despite the apparent importance of antibiotic treatment of bacterial infections, surprisingly little is known about the molecular functions of antibiotic actions in the bacterial cell. Here, we analyzed the molecular effects of ethambutol, a first-line antibiotic against infections caused by members of the genus Mycobacterium We find that this drug selectively blocks apical cell growth but still allows for effective cytokinesis. As a consequence, cells survive ethambutol treatment and adopt a pneumococcal cell growth mode with cell wall synthesis only at the site of cell division. However, combined treatment of ethambutol and beta-lactam antibiotics acts synergistically and effectively stops cell proliferation.
Ludwig-Maximilians-Universität, Fakultät Biologie, Planegg-Martinsried, Germany.
Karin
K
Schubert
Ludwig-Maximilians-Universität, Fakultät Biologie, Planegg-Martinsried, Germany.
Boris
B
Sieger
Ludwig-Maximilians-Universität, Fakultät Biologie, Planegg-Martinsried, Germany.
Fabian
F
Meyer
Ludwig-Maximilians-Universität, Fakultät Biologie, Planegg-Martinsried, Germany.
Giacomo
G
Giacomelli
Ludwig-Maximilians-Universität, Fakultät Biologie, Planegg-Martinsried, Germany.
Kati
K
Böhm
Ludwig-Maximilians-Universität, Fakultät Biologie, Planegg-Martinsried, Germany.
Angela
A
Rieblinger
Ludwig-Maximilians-Universität, Fakultät Biologie, Planegg-Martinsried, Germany.
Laura
L
Lindenthal
Ludwig-Maximilians-Universität, Fakultät Biologie, Planegg-Martinsried, Germany.
Nadja
N
Sachs
Ludwig-Maximilians-Universität, Fakultät Biologie, Planegg-Martinsried, Germany.
Gerhard
G
Wanner
Ludwig-Maximilians-Universität, Fakultät Biologie, Planegg-Martinsried, Germany marc.bramkamp@lmu.de.
Marc
M
Bramkamp
D000995:Antitubercular Agents / Q000494:pharmacology*; D002473:Cell Wall / Q000187:drug effects* / Q000378:metabolism; D048230:Corynebacterium glutamicum / Q000187:drug effects* / Q000254:growth & development*; D004977:Ethambutol / Q000494:pharmacology*; D009168:Mycobacterium phlei / Q000187:drug effects* / Q000254:growth & development*
D000995:Antitubercular Agents; D004977:Ethambutol